



## **Personalis, Inc. to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study**

August 7, 2019

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 7, 2019--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care will utilize Personalis' cancer immunogenomics platform, [ImmunoID NeXT™](#), for the investigation of biomarkers of response to a novel treatment paradigm in women with ovarian cancer. The basis of this trial, which evaluates the combination of Olaparib and Tremelimumab in women with recurrent BRCA-deficient ovarian cancers, is based on the work of Sarah Adams, MD, that indicated that immune priming with targeted cytotoxic therapy using a PARP-inhibitor can sensitize ovarian tumors to immune therapy and optimize patient survival. The clinical trial is being conducted at several ORIEN centers across the United States. For more information please visit [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02571725) identifier [NCT02571725](#).

"We are delighted to collaborate with Personalis on this study," said the principal investigator of the study, Dr. Adams, Associate Professor, Division of Gynecologic Oncology at the [UNM Comprehensive Cancer Center](#). "Comprehensive immuno-profiling will inform on biomarkers of response for this experimental treatment in women with BRCA1 or BRCA2 germline mutated ovarian cancers, for which there aren't standard curative measures."

Personalis ImmunoID NeXT™ Platform provides a comprehensive interrogation and analysis of ~20,000 genes in both DNA and RNA. The platform is an end-to-end solution for immuno- and precision oncology biomarker discovery applications, simultaneously enabling the analysis of: tumor escape mechanisms (including HLA typing and somatic mutation detection), immune repertoire profiles, neoantigen load, tumor mutational burden (TMB), microsatellite instability (MSI), oncoviruses, and immune checkpoint gene expression.

### **About Personalis, Inc.**

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's [NeXT™ Platform](#) is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis [Clinical Laboratory](#) is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit [www.personalis.com](http://www.personalis.com) and follow Personalis on Twitter ([@PersonalisInc](#)).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190807005181/en/>

Source: Personalis, Inc.

### **Investor Relations Contact for Personalis:**

Caroline Corner  
[investors@personalis.com](mailto:investors@personalis.com)  
[www.westwicke.com](http://www.westwicke.com)  
415-202-5678

### **Media Contact for Personalis:**

Jennifer Havlek  
[pr@personalis.com](mailto:pr@personalis.com)  
[www.personalis.com](http://www.personalis.com)  
650-752-1300